Patients with fistulizing inflammatory bowel disease are traditionally difficult to treat. This patient population often experiences delayed or insufficient healing of fistulas using current standard regimens including anti biotics, immunomodulators, antitumor necrosis factorα drug, placement of setons, and surgical repair. Several studies over the last ten to fifteen years have been conducted using stem cell therapies with promising results in this patient population. These studies show stem cell therapy in fistulizing disease to be successful in healing between 60%88% compared to currently 50% with infliximab. Moreover, remission was seen 24 wk to 52 wk in these studies. Further research with a multiapproach treatment using medications, stem cell therapy, and surgical interventions will likely be the future of this innovative treatment approach.
INTRODUCTION
Inflammatory bowel disease (IBD), including Crohn's disease (CD), ulcerative colitis (UC), and IBD-unclassified, is a very complicated unique spectrum of dis ease processes, ranging from relatively asymptomatic to daily complications of significant pain and fistulizing disease. While fistulizing disease primarily occurs in CD, sometimes patients are initially diagnosed with UC, which later is realized to actually be CD. Furthermore, UC patients sometimes develop fistulas for other rea sons besides their IBD. Unfortunately, little is known on which afflicted individuals will progress despite signs and symptoms with approximately 25% of CD patients developing fistulas within 20 years of diagnosis [1] . Some patients will do well and achieve complete remission with newer biological agents (i.e., vedolizumab) and placem ent of setons, while others will continue to be refractory in their disease course. Antibiotics, immunomodulators, and antitumor necrosis factoralpha (TNFα) drugs all have been utilized for fistulizing disease with less than ideal response rates: 90% recurrence with antibiotics and 50% recurrence with infliximab [2] . Furthermore, onethird of patients do not respond to antiTNFα medications and 10% of patients are nonresponders to existing medications [3] . Stem cell therapy is an emerging treatment for these difficult to treat patients with fis tulizing CD.
In this review, the authors aim to highlight the pro gression of stem cell therapies in patients with refractory CD with fistulizing disease. A literature search of clinical trials in humans was performed with PubMed through April 2018 using keywords including stem cell therapy, fistulas, fistulizing, IBD, and CD. The searches were limited to English language, and excluded comments, editorials, or letters. The outcomes of safety and efficacy using this innovative treatment are presented throughout and are outlined after each section of type of stem cell modality in Tables 15.
Four main groups of stem cell therapies exist which include embryonic, tissuespecific, mesenchymal, and induced pluripotent stem cells. Most studies evaluating treatment of fistulizing disease for IBD patients utilize mesenchymal stem cell (MSC) therapy, whether au tologous or allogeneic in nature. MSC are stromal cells surrounding other tissues and organs that are able to undergo angiogenesis of the cells they are derived from and are available to help with immunomodulatory effects. This includes adipose tissue and bone marrow cells. Three criteria for MSC in vitro must be met per the International Society for Cellular Therapy, which include differentiation potential, i.e., adipogenic linea ges, expression of surface antigens including human 494 WJCC|www.wjgnet.com
Turse EP et al . Stem cell therapy for fistula in CD leukocyte antigen DR, CD79a, CD19, CD14, CD11b, CD45, CD34, CD105+, CD90+, CD73+, and ability to adhere to plastic [4] . Limited studies exist in animal models and human trials, yet there has been an emergence of research in this area within the last ten years. The majority of these studies had the same exclusion criteria unless otherwise specified below. These includ ed evidence of any infections, the need for antibiotics or immediate surgery, unwilling to use contraceptives, pregnant or breastfeeding, presence of complex fis tulas with more than two openings or malignancy wi thin the past five years, and any evidence of endorgan failure. Fistulas in most studies were a mix of trans sphincteric, suprasphincteric, and extrasphincteric and sometimes rectovaginal. No studies using stem cell therapy specifically for fistulizing disease commented on development of graft versus host disease. Most side effects were limited for stem cell therapy with fistulizing disease as local injection was used. However, with he matological stem cell therapy infusions, the most com mon adverse effect seen was systemic infection.
AUTOLOGOUS ADIPOSE TISSUE DERIVED STEM CELL THERAPY TRIALS
Autologous adipose tissue derived stem cell (ASC) therapy is a type of MSC therapy derived from one's own adipose tissue. In 2003, one of the first case reports for fistulizing CD using ASC for CDrelated rectovagin al fistulas (CRRVF) was reported [5] . This utilized ASC for a patient with refractory disease to infliximab and placement of setons, with resultant resolution of sy mptoms in one week after local injection with no reoc currence after three months.
Lee et al [6] studied 33 patients with fistulizing di sease using autologous ASC proportional to fistula surface area by conducting a nonrandomized, single group assignment openlabel phase 1 study. Using pho tography, patients were documented on weeks 4, 6, and 8 and if complete healing was not found at week 8, reinjected with ASC. The authors defined complete healing as "complete closure of fistula tract and internal and external openings, without drainage or any sign of inflammation" [6] . Here, promising results of ASC therapy for fistulizing disease were seen with 79% of patients showing complete closure after a first dose, and 88.5% of patients not having recurrence at the oneyear mark. This study had a wide variety of patients regarding their duration of CD and duration of fistula.
Next, Cho et al [7] studied autologous ASC in a phase 1 nonrandomized, openlabel dose escalation trial with ten patients enrolled. Three dosing groups with three patients in each were evaluated with dosing given at fourweek intervals and patients evaluated at eight weeks, and four, six, and eight months. Fifty percent of patients after a single injection observed complete healing, compared to 16% with prior studies of fibrin glue. These patients who showed healing at eight we 
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García-Arranz et al [11] 2016 RV Turse EP et al . Stem cell therapy for fistula in CD eks sustained healing at eight months. The authors compared this to a fistula recurrence rate of 43% of patients with CD treated with infliximab [7] . In addition, Cho et al [8] went on to analyze 41 of 43 patients in their previous phase 2 trial with dosage proportional autologous ASC administration for an ad ditional year in a retrospective chart review of these patients. They evaluated sustainability and efficacy of ASC applied and further documented safety 24 mo after ASC administration. Patients were excluded if they had operations during that timeframe and three patients met this criterion; four patients were excluded due to lack of data. Results showed 82% of patients had resolution of their fistulas and durability was 80% (P ≤ 0.0001) at 12 mo and 75% (P ≤ 0.001) at 24 mo. Furthering stem cell therapy studies, Dietz et al [9] conducted a phase 1 single center nonrandomized trial evaluating stem cell treatment for patients remaining
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Table 5 Summary of all clinical trials evaluating stem cell therapy for fistulizing inflammatory bowel disease
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Sanz-Baro et al [16] Turse EP et al . Stem cell therapy for fistula in CD on biologic therapy of infliximab, adalimumab, and cer tolizumab. Twelve patients were given a stem cell load ed plug (MSCMATRIX) with complete clinical healing in 75% of the population at three months, and 83.3% within six months. MRI was used to define characteristics of treated fistula tracts at baseline and six months to further confirm healing.
AUTOLOGOUS BONE MARROW DERIVED STEM CELL THERAPY TRIALS
Between 2007 and 2014, Ciccocioppo et al [10] looked at fistulizing CD assessing patients with autologous bone marrowderived MSC (BMMSC) for safety and efficacy. The authors found that fistula relapsefree survival was 88%, 50% and 37% at one, two, and fiveyear follow up with no adverse events (AE). Thus, they concluded that BMMSC was safe and efficacious for fistulizing CD.
ALLOGENEIC ADIPOSE TISSUE DERIVED STEM CELL THERAPY TRIALS
GarcíaArranz et al [11] conducted a phase 12 non randomized, openlabel trial with ten patients using allogeneic ASC for rectovaginal fistulas. Primary end point was safety and feasibility to treat CRRVF, and patients were followed at 1, 4, 8, 12, 24, and 52 wk after ASC administration. If complete reepitheliali zation was not obtained by week 12, a second dose of ASC was administered. CRRVF was defined as healed "when the vaginal and rectal walls showed complete reepithelialization and absence of vaginal drainage, including feces, flatus or suppuration". Nine patients had their fistula cured during the study, yet fistula re occurrence occurred in seven of these patients. Due to patients being excluded for reasons such as need for biologic therapy or surgeries, the final efficacy rate for sustained fistula healing at 52 wk was 60% (three of five patients did not have reoccurrence). It was con cluded that the primary endpoint was met as the study was found to be safe and feasible as a treatment option. de la Portilla et al [12] analyzed in a phase 12 open label singlearm nonrandomized multicenter study 24 patients, who were given allogeneic expanded adipo sederived ASC (eASC) for complex perianal fistulas in CD. The endpoint was to determine safety and efficacy in this population. Patients underwent initial magnetic resonance imaging (MRI), and then eASC injection with a second injection if incomplete closure was found at 12 wk, with conclusion of the study at 24 wk. The same definition of closure as the Lee et al [6] study was used with evaluation at weeks 10, 12, 22, and 24 by both the treating physician and a blinded gastroenterolo gist/surgeon. The study found that 69.2% of patients had reduction in their fistula, with 38.1% of patients achieving complete closure at week 12 and 65.3% at week 24. Thus, it was concluded that eASC were safe and efficacious in the treatment of complex perianal fistulas. Panés et al [13] authored a phase 3 randomized, do ubleblind, parallelgroup, placebocontrolled, multi center trial utilizing eASC as treatment in complex pe rianal fistula CD patients known as the ADMIRE CD study. Patients with stenosis, CRRVF, diverting stoma, or abscesses > 2 cm were additionally excluded to the ab ove criteria. Inclusion criteria for the study were patients with refractory disease to immunologic, antibiotics, or biologics such as antiTNF drugs. Closure was a similar definition as the above studies. Two hundred and twelve patients were randomly assigned, with 88 vs 83 patients at completion of the 24 wk. Overall, 50% of patients treated with eASC either solo or in combination with medical treatment achieved remission compared to 34% in the placebo group (P = 0.024) [13] . Treatment was also documented to be safe and efficacious with similar adverse reactions occurring more in the placebo group, thus being secondary to the nature of disease course in CD.
Panés et al [14] extended the ADMIRE CD Study from 24 wk to 52 wk and documented both clinical remission and combined remission. They defined this as "clinical assessment of closure of all treated external openings that were draining at baseline and the absence of collections > 2 cm." The trial concluded that eASC is still superior to placebo with clinical remission in 59.2% Cx601 vs 41.6% placebo (95%CI: 4.131.1; P = 0.013) and 56.3% vs 38.6% (95%CI: 4.231.2; P = 0.010) in combined remission. Wainstein et al [15] also published a single center prospective observational pilot study conducted betw een 20132016 and included nine patients. Two stages were included in this study which was (1) "examination under anesthesia, fistula mapping, drainage and seton placement" and (2) setons removed four to six weeks with subsequent debridement and ASC then injected with biological plug formation. There were three clas ses of treatment results: complete healing, partial hea ling, and no healing. Partial healing was defined as external fistula opening remaining but with decrease of > 50% in size. This study found complete healing in 10/11 patients' fistulas and partial healing in 1/11 [15] . Conclusions were made that excellent success rates can be made for fistulizing CD with a multiapproach treatment method including ASCs, platelet rich plasma, and endorectal advancement flaps.
ALLOGENEIC BONE MARROW DERIVED STEM CELL THERAPY TRIALS
Molendijk's team conducted a randomized, double blind, placebocontrolled, doseescalating study using allogeneic bonemarrow MSCs with surgical treatment for 21 patients with refractory perianal fistulizing CD [1] .
The study used either MSCs from five different donors
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Turse EP et al . Stem cell therapy for fistula in CD or normal saline5% albumin solution as placebo with surgery performed by two surgeons with expertise in IBD. Fistula healing was documented by photography at weeks 0, 12, and 24, in addition to finger pressure at external openings and MRI at week 12. Endpoints were absence of discharge and absence of collections of > 2 cm on MRI. Results were 66.7%, 85.7%, and 28.6% fistula healing for the three groups at week 24 compared to placebo (P = 0.06 group 2 vs placebo) [1] . The study concluded that allogeneic bonemarrow MSCs are superior in promoting fistula healing compared to placebo for patients with refractory perianal fistulizing CD.
MIXED STEM CELL TREATMENT MODALITIES
Interestingly, there was a case study published in 2015 that included five pregnant females with fistulizing CD analyzing their reproductive outcomes [16] . Of this patient population, three had CRRVF and two had perianal fis tulas and had undergone ASC injection with resolution of their fistulas and subsequent ability for pregnancy (between 17 mo to 2 years). Thus, three patients re ceived autologous and two patients had received allo geneic ASC prior to conception. All five patients were in their 30s during administration of ASC, and mid thirties to early forties for age at gestation [16] . All but one patient had 1824 mo between ASC and gestation. After their pregnancies, the patients were given data collection sheets. Two of the five patients experienced gestational complications, namely being first trimes ter miscarriages (no treatment during pregnancy) and fetal growth restriction and small for gestational age (azathioprine during pregnancy). Of the patients who gave birth, all four patients underwent cesarean section with only one newborn malformation occurring, which was syndactyly with clinodactyly [16] .
DISCUSSION
Suggestions and Practical Guidance
Patients who present with continued fistulas from th eir IBD despite other medical and surgical therapies should be referred to centers that are utilizing stem cell therapies. Such patients can have relief and resolution of anxiety and frustration of their disease process with this novel treatment. Physicians caring for this patient population who consider such therapies should make sure to counsel patients on the risks versus benefits including the commonly seen AE and significant adverse effects (SAE) mentioned above. Additionally, patients should know that if they undergo allogeneic transplantation they may fail to harvest enough stem cells for treatment. Yet, the authors of this paper and the authors of the literature reviewed here are excited for future studies and a novel treatment for a complicated disease.
CONCLUSION
In this review, we highlight the progression of utilization of stem cell therapy in fistulizing IBD, specifically CD. While still early along in this evaluation process, these therapies do offer a lot of potential for a difficult to treat population. Likely because of its immunomodulatory ability with differentiation and suppression of prolifera tion, stem cell therapies appear to be a promising trea tment option for a sizeable population of CD patients with fistulizing disease.
FUTURE PERSPECTIVES
Currently on the horizon, there are four clinical trials registered for fistulizing CD. Three of these studies are recruiting and one is still pending recruitment. Three of these will be nonrandomized, one of these will be randomized singleblind, and the majority will be utilizing autologous stem cells [17] . Studies need to be streamlined in the amount of stem cells used and the type of cells harvested such as allogeneic versus autologous hosts and bone marrow versus adipose tissue. Since there does not appear to be a benefit to bone marrow harvesting thus far, we believe that studies should focus on adiposederived stem cells, either autologous or allogeneic. Comparing studies to current treatment rates of fistula healing, which is less than 50%, stem cell therapy for fistulizing CD appears to be beneficial as the majority of studies claim 60%88% fistula healing and remission observed at 2452 wk. Studies even showed benefit of remission five years out from administration [10] . Moreover, these studies show that stem cell treatment for fistulizing disease is safe with very few AE or SAE, with the majority including pain, bleeding, or abscesses. Most AE or SAE observed were due to the underlying nature of IBD itself.
